Abstract
Most drugs and xenobiotics induce the expression of cytochrome P450 (CYP) enzymes, which reduce the bioavailability of the inducer and/or co-administered drugs. Therefore, evaluation of new drug candidates for their effect on CYP expression is an essential step in drug development. The available methods for this purpose are expensive and not amenable to high-throughput screening. We developed a fluorescence-based in vivo assay using transgenic Caenorhabditis elegans worms that express the green fluorescent protein (GFP) under the control of various CYP promoters. Using this assay, we found striking similarities between the worm CYPs and their human orthologs in their response to treatment with various drugs. For example, the antibiotic rifampicin, one of the strongest inducers of the human gene CYP3A4, was the strongest inducer of the worm ortholog CYP13A7. Since worms can be easily grown in liquid medium in microtitre plates, the assay described in this paper is suitable for the screening of a large number of potential lead compounds in the drug discovery process.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- CYP:
-
cytochrome P450
- GFP:
-
green fluorescent protein
- PBS:
-
phosphate buffered saline
- PI-CYP:
-
pharmacologically important human CYP
- RT-PCR:
-
reverse transcriptase polymerase chain reaction
References
Barry M, Gibbons S, Back D and Mulcahy F 1997 Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations; Clin. Pharmacokinet. 32 194–209
Brandon E F A, Raap C D, Meijerman I, Beijnen J H and Schellens J H M 2003 An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons; Toxicol. Appl. Pharmacol. 189 233–246
Brenner S 1974 The genetics of Caenorhabidits elegans; Genetics 77 71–94
Dickens M 2004 Induction of cytochrome P450; Curr. Top. Med. Chem. 4 1745–1766
Driscoll M and Gerstbrein B 2003 Dying for a cause: invertebrate genetics takes on human neurodegeneration; Nat. Rev. Genet. 4 181–194
Francis R, McGrath G, Zhang J, Ruddy D A, Sym M, Apfeld J, Nicoll M, Maxwell M, et al 2003 aph-1 and pen-2 are required for Notch pathway signaling, gamma-secretase cleavage of βAPP, and presenilin protein accumulation; Dev. Cell 3 85–97
Goodwin B, Hodgson E and Liddle C 1999 The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module; Mol. Pharmacol. 56 1329–1339
Gerisch B, Weitzel C, Kober-Eisermann C, Rottiers V and Antebi A 2001 A hormonal signaling pathway influencing C. elegans metabolism, reproductive development, and life span; Dev. Cell 1 841–851
Guengerich F P 1999 Cytochrome P-450 3A4: regulation and role in drug metabolism; Annu. Rev. Pharmacol. Toxicol. 39 1–17
Guengerich F P 2003 Cytochrome P450, drugs, and diseases; Mol. Interv. 3 194–204
Kraemer B C, Zhang B, Leverenz J B, Thomas, J H, Trojanowski J Q and Schellenberg G D 2003 Neurodegeneration and defective neurotransmission in a Caenorhabditis elegans model of tauopathy; Proc. Natl. Acad. Sci. USA 100 9980–9985
Kocarek T A, Schuetz E G, Strom S C, Fisher R A and Guzelian P S 1995 Comparative analysis of cytochrome p4503A induction in primary cultures of rat, rabbit, and human hepatocytes; Drug Metab. Dispos. 23 415–421
Madan A, Graham R A, Carroll K M, Mudra D R, Burton L A, Krueger L A, Downey A D, Czerwinski M et al 2003 Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes; Drug Metab. Dispos. 31 421–431
Menzel R, Bogaert T and Achazi R 2001 A systematic gene expression screen of Caenorhabditis elegans cytochrome P450 genes reveals CYP35 as strongly xenobiotic inducible; Arch. Biochem. Biophys. 395 158–168
Nebert D W and Russell D W 2002 Clinical importance of the cytochromes P450; Lancet 360 1155–1162
Nelson D R 2003 Comparison of P450s from human and fugu: 420 million years of vertebrate P450 evolution; Arch. Biochem. Biophys. 409 18–24
Niemi M, Backman J T, Fromm M F, Neuvonen P J and Kivisto K T 2003 Pharmacokinetic interactions with rifampicin: clinical relevance; Clin. Pharmacokinet. 42 819–850
Park J Y, Kim K A, Park P W, Park C W and Shin J G 2003 Effect of rifampicin on the pharmacokinetics and pharmacodynamics of gliclazide; Clin. Pharmacol. Ther. 74 334–340
Praitis V, Casey E, Collar D and Austin J 2001 Creation of lowcopy integrated transgenic lines in Caenorhabditis elegans; Genetics 157 1217–1226
Riddle D L, Blumenthal T, Meyer B J and Priess J R (eds) 1997 C. elegans II (New York: CSHL Press)
Sambrook J, Fritsch E F and Maniatis T 1989 Molecular cloning, a laboratory manual (New York: CSHL Press)
Silva J M, Day S H and Nicoll-Griffith D A 1999 Induction of cytochrome P450s in cryopreserved rat and human hepatocytes; Chem. Biol. Interact. 121 49–63
Wong L-L 1998 Cytochrome P450 monooxygenases; Curr. Opin. Chem. Biol. 2 263–268
Wolkow C A, Kimura K D, Lee M S and Ruvkun G 2000 Regulation of C. elegans life-span by insulin like signaling in the nervous system; Science 290 147–150
Yan Z and Cardwell G 2001 Metabolism profiling, and cytochrome P450 inhibition and induction in drug discovery; Curr. Top. Med. Chem. 1 403–425
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chakrapani, B.P.S., Kumar, S. & Subramaniam, J.R. Development and evaluation of an in vivo assay in Caenorhabditis elegans for screening of compounds for their effect on cytochrome P450 expression. J Biosci 33, 269–277 (2008). https://doi.org/10.1007/s12038-008-0044-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12038-008-0044-5